Sanjay D Goorachurn New CEO at Medisca

Sanjay D Goorachurn

Medisca, a global company specializing in personalized pharmaceutical solutions, is pleased to announce the appointment of Sanjay D. Goorachurn as the company’s new CEO, as founders, Tony Dos Santos and Maria Zaccardo, transition into strategic advisory roles as Chair and Vice Chair, respectively. Coinciding with the company’s 35th anniversary, this decision marks a significant milestone in Medisca’s history.

In 1989, Medisca opened its doors as a team of three with two products and a vision to bridge the gaps in patient care. Today, Medisca is a global leader in personalized medicine with more than 10 locations spanning 5 countries. Powered by a workforce of over 450 employees, Medisca offers a vast portfolio of more than 2,000 product solutions to meet the needs of diverse healthcare sectors.

Don Santos Comments

“Over the course of 35 years, Medisca has seen remarkable development, grounded in its people and dynamic entrepreneurial culture. With the addition of Sanjay’s unique set of experiences and skillset, we are confident that this marks the beginning of a new chapter for Medisca.”

As a seasoned intellectual property lawyer with over 30 years of experience, Goorachurn is regarded as one of the world’s leading IP strategists working closely with senior executives of private and public companies on maximizing the commercial value of a company’s innovation and IP assets. It is Goorachurn’s distinct expertise and first-hand experience in implementing transformative growth for complex and global companies that drew Dos Santos and Zaccardo to him back in 2016, when he joined the Medisca team as a strategic advisor.

“Sanjay’s history with Medisca was an essential element that led to our decision to bring him on as our new CEO,” said Dos Santos. “Over the last 8 years, Sanjay has built authentic relationships with many Medisca people and coached us through some very successful wins, including the advancement and protection of our key innovations. It was critical to us that the company’s next CEO be someone who not only has the capability to take us forward, but also shares the same fundamental values that define who we are.”

“My goal is to preserve the entrepreneurial legacy of Tony and Maria and carry forward the company’s vision to empower personalized wellness for all,” said Goorachurn. “My focus will be centered around empowering Medisca’s people, creating a more structured infrastructure for strategic growth, building key partnerships, and continuing to leverage innovative excellence that sets Medisca apart, while expanding our global presence.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”